Nicholas Likely to Drop Chikungunya Research (India)
This article was originally published in PharmAsia News
Nicholas Piramal India (NPIL) is expected to withdraw its proposal for a joint venture drug discovery research program with Laboratories Pierre Fabre of France due to the slow regulatory process. The research program was slated to develop the world's first vaccine for chikungunya, which has evolved into an epidemic after spreading throughout southern India and Maharashtra over the last two years. But the Central Drug Control Authority has yet to authorize the project. "We will have to drop the drug research plans for chikungunya, since the Drug Controller General of India (DCGI) is yet to sanction the project," said NPLI Director of Strategic Alliances Swati Piramal. In light of the delays, Piramal explained that there was little else the company could do. "It is almost six months since we applied." The new drugs require the DGCI's approval before they can enter the Indian market. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.